Join our daily newsletter At The Bell to receive exclusive market insights
- Universal Biosensors (UBI) enters into a collaboration agreement with Mayo Clinic Biopharma Diagnostics
- Mayo Clinic is one of the world’s most prestigious oncology research and treatment institutions
- The agreement covers multiple projects including UBI’s Tn antigen cancer biosensor and is for a three year term
- On market close for the day, Universal Biosensors was up 1.89 per cent to trade at 81 cents per share
Universal Biosensors (UBI) has entered into a collaboration agreement with Mayo Clinic Biopharma Diagnostics.
Mayo Clinic is one of the world’s most prestigious oncology research and treatment institutions based in Rochester Minnesota, US. The business is focused on integrated healthcare, education and research.
The agreement covers multiple projects including UBI’s Tn antigen cancer biosensor, a handheld device that can accurately measure a patient’s cancer status through monitoring of remission and recurrence.
The agreement is for a three year period and includes standard termination options.
UBI designs and develops electrochemical cells for use together with point-of-use devices across the healthcare, wine, food and agriculture industries.
Last month, Universal Biosensors signed a non-exclusive distribution deal with Vivelys SAS to distribute its Sentia wine testing platform device.
The wine testing platform is a new product and is currently being launched around the globe.
Vivelys is based in France and is focused on the analysis of grape vines and the ageing of wines in oak barrels through every stage of the winemaking process.
The parties’ distribution deal also had a three-year term.
On market close for the day, Universal Biosensors was up 1.89 per cent and to trade at 81 cents per share.
